Bridge to acquisition
Alzheimer's play Satori gets $15M in debt to reach IND, strategic deal
Bridge to acquisition
First generation gamma secretase inhibitors didn't work in Alzheimer's disease, but Satori Pharmaceuticals Inc. is betting that its more selective gamma secretase modulator